DS Healthcare Appoints Brijesh Patel, MS, PhD as Senior Vice President, R&D

Apr. 12, 2017 3:48 pm

POMPANO BEACH, FL / ACCESSWIRE / April 12, 2017 / DS Healthcare Group (NASDAQ: DSKX) today announced that Dr. Brijesh Patel has been named Senior Vice President, Research and Development, effective immediately. Dr. Patel joined the company in March 2014 as Director of R&D and has established many important new benchmarks in quality control systems, product stability studies, scientific research, and development of new technologies.

In his new leadership role, Dr. Patel will have extensive responsibility over all aspects of laboratory management and interaction with the operations team to establish manufacturing and quality control procedures. DS Healthcare's new laboratory will enable many new scientific experiments and includes: a fully equipped cell culture lab with a carbon dioxide incubator for growing human cells; cell culture laminar flow equipment; and new analytical equipment that includes a high-performance liquid chromatography system with a diode array detector for separation and quantification of ingredients on a nanoscale level. Dr. Patel will work closely with Chief Executive Officer, Daniel Khesin, to deliver many new innovations in the near future.

"We are delighted to appoint Dr. Brijesh Patel, who is making extraordinary contributions to our long-term vision and is overseeing highly sophisticated projects that will translate into many new innovations that will benefit consumers," said Khesin.

The Company will soon announce several new products that are a result of research and development efforts led by Dr. Patel, concurrent with the findings of several ongoing clinical trials.

About DS Healthcare Group

DS Healthcare Group Inc. develops novel biotechnology for topical therapies. It markets through online channels, specialty retailers, distributors, pharmacies, and physicians. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group, visit www.dshealthgroup.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan," or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, current litigation against the Company, ongoing regulatory investigations of the Company, Nasdaq's trading halt of the Company's common stock and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at www.sec.gov.

Investor Relations

DS Healthcare Group
(888) 404-7770 ext. 3

SOURCE: DS Healthcare Group

Accesswire IA
April 12, 2017 - 3:48 PM EDT

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market